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A CALIX[4]ARENE DERIVATIVE AND ITS SELECTIVE INTERACTION WITH DRUGS 
(CLOFIBRIC ACID, DICLOFENAC AND ASPIRIN)  . 
 
Angela F Danil de Namor1, Maan Al Nuaim1, Jose A Villanueva Salas1, Sophie Bryant1 and 
Brendan Howlin2, 1Laboratory of Thermochemistry and 2 Computational Research Group, 
Department of Chemistry, University of Surrey, Guildford, Surrey, GU2 7XH. 
 
ABSTRACT 
The synthesis and characterisation of a  partially substituted calix[4]arene, namely, 5,11,17,23-
tetra-tert-butyl,25,27-bis[aminoethoxy] 26,28-dihydroxycalix[4]arene are reported. Its interaction 
with commonly used pharmaceuticals (clofibric acid, diclofenac and aspirin) was investigated 
by spectroscopic (1 H NMR and UV), electrochemical (conductance measurements) and 
thermal (titration calorimetry) techniques. It is concluded on the basis of the experimental work 
and molecular simulation studies  that the receptor interacts selectively with these drugs. 
Preliminary studies on the selective extraction of these pharmaceuticals from water by the calix 
receptor are reported and the potential for a carrier mediated sensor based on this ligand for 
‘on site’ monitoring of pharmaceuticals is discussed.  
 
INTRODUCTION 
In the last few years contamination of water by pharmaceuticals has become a serious concern 
by environmental scientists.1-3 Pharmaceuticals can enter the aquatic environment through 
many sources resulting from their use for the treatment of humans and animals and can be 
excreted unchanged , as metabolites, as unused discharge or as residuals of drug 
manufacturers4-6 
Several methods have been reported for the removal of pharmaceuticals from water such as 
metal salt coagulation and excess lime/soda ash softening (no significant removal),7-9 
powdered activated carbon (slow kinetics of sorption,9,10 material becomes saturated over time, 
non-selective9,10). Chlorination (by products formed9,10 of unknown toxicity, removal rate is pH 
dependent which could not be controlled in a treatment plant environment11), ozonation12-14 
(oxidation by ozone is effective to remove most pharmaceuticals from water but the toxicity of 
ozone and by-products resulting from this process has adverse implications on human health 
and the environment), UV photolysis (Up to 80% removal only with very high input of 3000 mJ 
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cm-2. Inefficient.4), ion exchange (non-selective), reverse osmosis (90% of pharmaceuticals are 
removed  but it is expensive4). 
Diclofenac {2-[2-(2,6-dichlorophenyl)aminophenyl]ethanoic acid } is a non-steroidal anti-
inflammatory drug currently used to treat painful conditions resulting from arthritis, sprains and 
strains, gout, migraine, and other illnesses. Clofibric acid [2-(4-chlorophenoxy)-2-
methylpropanoic acid] is known as the active metabolite of a number of drugs currently used to 
reduce the levels of cholesterol in blood. Aspirin (acetyl salicylic acid) is one of the most 
frequently used drugs, it is an analgesic with pain relief and anti-inflammatory properties15. In 
small doses, aspirin is recommended to reduce the risks of heart attacks, angina and 
strokes.16,17 Side effects of this drug have been reported.18 These pharmaceuticals are widely 
detected in the environment.19 As far as diclofenac is concerned, methodologies used for its 
removal from water include electron beam radiation combined with a biological aerated filter,20 
pyrite catalysed Fenton oxidation,21 double templates- molecularly imprinted polymers,22 cork-
based activated carbon,23 poly-ethylenimine-modified chitosan beads,24 membrane 
bioreactors,25 and modified clays.26 In deriving the Margin of Exposure (MOE) of 
pharmaceuticals, calculated guideline values were based on comparisons made with maximum 
concentrations found in secondary treated effluents. It was then assumed that values in 
drinking water are likely to be lower and therefore their presence may not lead to a negative 
impact on human health.27 This may be the case for highly developed Countries but not 
necessarily for the Developing World where often water treatments are not always applied.  
Therefore, the threshold of toxicological effects due to the presence of pharmaceuticals in 
water needs further research. Another issue to be addressed is the need for establishing 
standard protocols for sampling and monitoring pharmaceuticals in water. Advanced monitoring 
techniques such as gas chromatography-mass spectrometry (GC-MS), ion chromatography-
mass spectrometry (I -MS) and others have been used to detect trace amounts of these 
compounds. Again these techniques are not always available and all of them require the 
transport of samples from the site to the laboratory. Therefore, efforts are required for ‘on site’ 
monitoring of pharmaceuticals in water. 
In technologies and monitoring devices aiming for the removal/detection of pollutants from/in 
contaminated sources it is imperative to introduce the concept of selectivity (ability of the 
decontaminating agent to recognise one species relative to others), often confused with 
specificity (recognition of only one particular target while discriminating against others). 
Selectivity is one of the main features of Supramolecular Chemistry28 and therefore it is 
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surprising to find that this field has not been explored for the removal/ monitoring of 
pharmaceuticals from/in water. Calix[4]arenes ( products of the condensation reaction of p- 
substituted phenol and formaldehyde in basic medium) are versatile receptors29-32. These 
receptors can be easily modified through the lower and upper rims and a number of derivatives 
are known to interact with ionic (through the hydrophilic cavity) and neutral (through the 
hydrophobic cavity   situated between the phenyl rings) species.33,34 The importance of 
fundamental studies in searching for applications is a relevant issue to address in the design of 
monitoring systems for the detection of pollutants as well as for the development of novel 
technologies for their removal from contaminated sources and most reports in the literature 
indicate that this is not often the case.  
In this paper we report an investigation involving a calix[4]amine derivative, 1, and its 
interaction with currently used pharmaceuticals, namely diclofenac, aspirin and clofibric acid. 
(Fig. 1) The selection of the amine functionality in the structure of 1 is based on its great affinity 
for the proton. 
 
 
 
 
 
 
 
 
 
Thus fundamental studies using a variety of techniques (spectroscopic, electrochemical and 
thermodynamic) involving this receptor and these pharmaceuticals are explored to assess the 
selectivity of 1 for these pharmaceuticals as the basis for environmental applications. 
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Figure 1. Chemical structures of chlofibric acid, diclofenac and aspirin 
 
EXPERIMENTAL 
The synthesis of 1 was carried out according to the following Scheme, 
 
Scheme 1. Synthetic procedure used for the preparation of L1 and 1 
The procedure applied by Danil de Namor and Shehab35 for the synthesis of calix[4]pyrrole 
derivatives was adapted for the preparation of L1 and 1. 
Synthesis of L1 calix[4]arene derivative38 
Thus in a three-neck round bottom flask (500 ml) containing a magnetic stirrer at room 
temperature under an inert atmosphere, p-tert-butyl calix[4]arene (97% HPLC, Sigma- 
Aldrich,10.293 g, 15.862 mmol), 18-crown-6 (Fluka, 99 %, 1.004 g, 3.799 mmol) and potassium 
carbonate (Fisher Scientific, 99.99%, 18.087 g, 130.869 mmol ) were dissolved in dry 
acetonitrile (Fisher Scientific, HPLC grade, 99.99% ,200 ml). Bromoacetonitrile (Aldrich, 97 %., 
7.394 g, 61.643 mmol) dissolved in acetonitrile (20 ml) was added drop-wise. The reaction 
mixture was heated in an oil bath at 75 °C and refluxed for 24 hours under vigorous stirring. 
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The reaction was monitored by thin layer chromatography using a mixture of hexane: ethyl 
acetate (8:2) as the developing solvent. After 24 hours the reaction mixture was allowed to cool 
down to room temperature. The solvent was removed under reduced pressure and a yellow 
solid was obtained. The solid was dissolved in dichloromethane (Sigma-Aldrich, ≥ 99 %), 
filtered gravitationally and the solvent was removed under reduced pressure. Methanol (Sigma-
Aldrich, HPLC grade, 99.7 %) was added to the resulting oil which was broken by sonication. 
Afterwards the solid was filtered and washed with cold methanol. The solid was left in a 
vacuum drier at 90o C. The product obtained in 70% yield was characterised by 1H NMR 
spectroscopy: 1H NMR (500 MHz, in CDCl3) δ (ppm); 7.11 (s, Ar-H, 4H), 6.72 (s, Ar-H, 4H), 
5.540 (s, OH, 2H), 4.80 (s, O-CH2, 4H), 4.19 (d, CHax, 4H), 3.42 (d,CHax )1.34 (s, CH3, 18H), 
0.87 (s, CH3, 18 H). 
 
Synthesis of 5, 11, 17, 23 tetra-p-tert-butyl, 25, 27- bis[aminoethoxy], 26, 28 
dihydroxycalix[4]arene, 1 36 
A solution of L1 (9 g, 21.45 mmol) was dissolved in dry THF (Scientific, HPLC grade, 99.99%, 
100 ml) and stirred in an ice bath until the temperature reached 0°C, LiAlH4 (95%, Sigma-
Aldrich, 1.896 g, 49.95 mmol) was dissolved in freshly dried THF then added drop-wise to the 
reaction mixture with continuous stirring for four hours and the temperature was kept at 0°C. 
The reaction was monitored using TLC and a hexane:ethyl acetate (8:2) mixture as the 
developing solvent, (10 ml, 20%). Then an aqueous solution of NaOH was added, followed by 
distilled water (10 ml). A white precipitate was obtained. The undesired white precipitate was 
filtered gravitationally and the solvent was evaporated by using a rotary evaporator. A white 
solid was obtained and dried under vacuum at 90° C. The product obtained in 60 % yield was 
characterised by 1H NMR spectroscopy, (500 MHz, in CDCl3), δ (ppm), 7.03 (s, Ar-H, 4H), 6.96 
(s, Ar-H, 4H), 5.2 (s, OH, 2H), 4.34 (d, Ar-CH2ax-Ar, 4H), 4.06 (t, OCH2, 4H), 3.37 (d, Ar-CH2eq-
Ar, 4H), 3.3 (t,N-CH2), 1.2 (s, CH3, 18H),1.09(s,CH3,18 H). 
NMR measurements 
1H NMR measurements were carried out at 298 K using a Bruker AC-500 MHz. 1H NMR 
titrations were carried out by adding increasing amounts of known concentrations of the 
pharmaceuticals (diclofenac, aspirin and clofibric acid, all from Aldrich) dissolved in CD3CN 
(Cambridge Isotope Laboratories, 99.8%) to the NMR tube containing a known concentration of 
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the receptor in the same deuterated solvent. Chemical shift changes of the receptor after each 
addition of the drug were recorded. Subtracting the chemical shifts for the free receptor r from 
those of the complex, c, the chemical shift changes  were calculated from Eq.1  
 
c r           Eq 1 
 
Conductometric measurements 
The conductivity cell constant was determined according to the method described by Jones 
and Bradshaw37 as previously reported.38 
 
Conductometric titrations were carried out by the gradual addition of the receptor solution in 
acetonitrile to the conductivity cell containing the targeted guest in the same solvent at 298.15 
K. For these measurements, the conductivity cell connected to a thermostated water bath and 
loaded with the guest solution in acetonitrile (25 ml). Then the electrodes were immersed into 
the cell containing the solution under continuous stirring during the course of the titration. 
Accurate aliquots of the receptor were gradually added to the guest solution in the same 
solvent, the resistance was recorded after each addition. The molar conductance, Λm (S cm2 
mol -1) was calculated. 
UV measurements  
UV-visible spectrophotometric measurements were taken on a Cecil CE7200 
spectrophotometer. UV-Vis spectra were recorded in the 200-400 nm range using 1 cm quartz 
cell to find the wavelength of maximum absorption. For the spectrophotometric titrations, 
aliquots of a solution of 1 in acetonitrile were added to the UV cell containing a solution of the 
targeted drug in the same solvent. 
Calorimetric measurements 
The reliability of the isothermal calorimeter (ITC) was checked by carrying out the standard 
reaction between Ba (II) and 18- crown- 6 in water at 298.15 K suggested in the literature39 
 
2 2 2
2 2
( ) ( )18 6 [ (18 6)]H O H O H OC Ba Ba C
       Eq. 2 
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The Nano- ITC measurements were carried out in degassed acetonitrile at 298.15 K. For 
assessing complex formation, a solution of 1 (1 mM) in acetonitrile was placed in the 
calorimetric cell (1.8 cm3). Solutions of each guest (20 mM) in the same solvent were added (5 
or 10 µL) successively into the host solution in the same solvent with a 300 s interval between 
each injection. Corrections for the heat of dilution were applied. The Nano ITC is connected to 
a personal computer that included the software ITCRun which follows the information and the 
status of the reaction taking place.  
Molecular modelling  
Modelling was carried out using MOE 2015.10.40 Models were built using the BUILDER module 
and energy minimised with the MMFF94X force field.41 A distance dependent van der Waals 
cut-off was used of 8Å (below this distance atoms were treated normally) and van der Waals 
interactions were discounted after 10Å. A dielectric constant of 1 was used for atoms below the 
lower cut-off distance and a value of 80 was used above. Minimisation was carried out using 
the smart minimiser that combines steepest descents, conjugate gradients and Newton-
Raphson methods as appropriate. Minimisation was carried out to a convergence criterion of 
0.0042 RMS (kJ/mol/Å2) 
Extraction of pharmaceuticals from water  
Preliminary experiments to assess the effect of the mass of the receptor, pH and temperature 
as well as the kinetics of the extraction process were carried out as previously described.42 
Aliquots were taken and analysed by UV spectrophotometry at 280 nm. The uptake capacity of 
1 was determined in batch experiments using a constant amount of the receptor (0.1 g) and 
aqueous solutions containing different concentrations of the pharmaceutical (9.10-5 – 4.4.10-4 
mol.dm-3). The tubes containing the mixture were then placed in a water bath and the 
temperature was maintained at 298 K. Samples were left overnight to equilibrate and then 
analysed by UV spectrophotometry. The uptake capacity, qeq (mmol g-1), was calculated using 
eq. 
 
Eq. 3 
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In Eq.3, V denotes the sample volume (cm3), ci and ceq   are the initial and the equilibrium 
concentrations (mmol /dm3) respectively, m is the amount of the receptor used.  
RESULTS AND DISCUSSION 
Interaction of 1 with pharmaceuticals 
Several analytical techniques were used to assess the interaction of 1 with aspirin, clofibric acid 
and diclofenac in acetonitrile such as 1H NMR, conductance, UV spectrophotometry and 
titration calorimetry.The lack of solubility of the receptor in water led us to select acetonitrile as 
the solvent. A further advantage of the use of this solvent is that the drugs are unlikely to be 
well solvated in this medium. In this way solvent-receptor competition for the drug decreases 
substantially and consequently the strength of guest-receptor interactions increases as 
previously discussed by Danil de Namor and co-workers.33 
As far as the 1H NMR measurements are concerned, the results in CD3CN  listed in Table 1 
show the chemical shifts of the free receptor, , and the chemical shift changes, , for the 
receptor upon the addition of the pharmaceutical. No chemical shifts changes were found by 
the addition of other drugs containing carboxylic functionalities such as ciprofloxacin (antibiotic 
used against a wide range of bacterial infections)43, aurintricarboxylic acid (inhibitor of RNA 
enzymes)44 , nalidixic acid45 and ibuprofen (anti-inflamatory drug)46 . As far as the free receptor 
is concerned, quite clearly 1 adopts a quasi perfect ‘cone’ conformation in solution as reflected 
in the difference observed in the chemical shifts of the axial and equatorial protons (ax-eq = 
1.03 ppm).47 This conformation is due to the presence of hydrogen bond formation between the 
phenolic hygrogen and the ethereal oxygen of the pendant arms of the receptor. 
 
Table 1. Chemical shift changes (in ppm) for the receptor protons as a result of the addition of 
the drugs to the receptor solution in CD3CN at 298 K. 
 H-1 H-2 H-3 H-4 H-5 H-6 H-7 H-8 N-H 
Free L 1.20 1.16 7.24 7.17 3.39 4.32 4.01 3.22 2.17 
Clofibric acid - - - - 0.06 -0.21 -0.09 0.15 0.32 
Diclofenac - 0.01 0.01 - - -0.21 0.14 0.17 0.21 
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Aspirin - - - - 0.08 -0.11 0.25 0.24 0.29 
 
It was previously demonstrated38 for an homologous receptor, namely 5,11,17,23-tetrakis-
[(diethylamine)ethoxy)]calix[4]arene, in the solid state (X ray diffraction studies) and in solution. 
that the ax-eq= 1.02 ppm in CD3CN for this homologous receptor is practically the same as 
that for 1. Furthermore acetonitrile was found in the hydrophobic cavity of the receptor. Also the 
X ray structure of 2 showed acetonitrile in the hydrophobic cavity of the receptor.Previous 
studies from our group in this solvent demonstrated that this process is also observed in 
solution.48 In fact, this is also the case for 1 as assessed from the chemical shift changes 
observed for the aromatic protons of this receptor in moving from CDCl3 to CD3CN where 
downfield chemical shifts of 0.21 and 0.19 ppm are observed.  
Further conformational changes are also observed in the bridging methylene protons during the 
complexation or protonation process The equatorial protons become less shielded relative to 
the free receptor particularly for clofibric acid and diclofenac ( -0.21 ppm) while for aspirin this 
effect is less pronounced (-0.11 ppm) while the equatorial protons are slightly deshielded 
relative to the uncomplexed receptor. A direct consequence of that, is a decrease in the shift 
difference between each pair of doublets of the ArCH2Ar system, from the free to the complex 
ligands (from 1.03 to 0.76 ppm for aspirin and to 0.66 ppm for clofibric acid and diclofenac), 
Significant downfield chemical shift changes are observed for H-7, H-8 and the NH proton as a 
result of an interaction between the amino group of the receptor and the proton of the 
carboxylic functional group of the drug.The most significant chemical shift changes are found 
for the NH proton. In an attempt to explain the differences observed in the  values for the 
NH proton for these pharmaceuticals (Table 1) the pKa values in water reported in the literature 
are considered48 (pKa, values are 3.0, 3.5 and 4.16 for clofibric acid, aspirin and diclofenac 
respectively)  due to the unavailability of these data in acetonitrile. Although the absolute pKa 
values of these drugs in the latter solvent are expected to differ significantly from those in water 
due to the medium effect, the order would be the same . It is therefore concluded that the 
downfield shift of the NH proton of 1 is strongly dependent of the degree of dissociation of the 
acid. This is further corroborated by i) 1H NMR titrations carried out in CD3CN. Representative 
examples for the titration of 1 with clofibric acid (a) and diclofenac (b) are given in Figure 2 
where  values obtained by the addition of these drugs to 1 are plotted against the drug/1 
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molar ratio where the most pronounced chemical shift changes are observed for the NH 
protons and to a lesser extent for H-7 and H-8. 
ii)  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 1 H NMR titration of 1 with clofibric acid (a) and diclofenac (b) in CD3CN at 298 K 
 
ii) The lack of interaction with other drugs tested given that  these behave as relatively weak 
acids in water  as reflected in their pKa values which are 6.09 , 6.1 and 4.54 respectively for 
cyprofloxacin49 ,nalidixic acid50 and ibuprofen 51 and are expected to be undissociated in 
acetonitrile 
 Therefore we proceeded with conductometric titrations which as previously demonstrated49,33 
can provide information on the composition of the complex as well as identifying whether the 
receptor-drug interaction is the result of hydrogen bond formation or a proton transfer reaction 
(from the pharmaceutical to the calixarene amine derivative) or both. To ensure that the 
receptor was not protonated its conductance was measured in MeCN prior to proceeding with 
(a) 
(b) 
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the titrations. No conductance was observed. However the conductometric curves  for the 
titration of these drugs with the receptor in acetonitrile provide a great deal of information. 
Figure 3 shows the titration of clofibric acid (a), diclofenac (b)  and aspirin (c) with 1 in MeCN 
and  at 298,15 K where the molar conductances , Λm (S.cm2.mol-1) are plotted against the 
1:drug concentration ratios. 
 
 
 
(a) 
(b) 
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Figure 3. Conductometric titrations of 1 with (a) clofibric acid (b) diclofenac and (c) aspirin in 
acetonitrile at 298.15 K 
 
The conductometric titration curve for aspirin  was found to show hardly any curvature to define 
the composition of the interaction with this drug and therefore a UV titration was carried out. As 
shown in Figure 4 , a complex of 1:1 stoichiometry is formed between this drug and 1 
 
 
Figure 4. UV titration of aspirin with 1 in acetonitrile at 298 K. 
 
Interpretation of these data shows that  
0 
0.4 
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i) Prior to the addition of the receptor, the drugs are highly associated in this solvent 
as reflected by the low conductance observed even at low concentrations. 
ii) Upon addition of 1, a significant increase in conductance is observed which must 
be attributed to a proton transfer reaction from the drug to the amine functional 
group of the receptor  
iii) The composition of the complex appears to be 1:1 for aspirin which   differs from 
those for clofibric acid and diclofenac where two slight breaks are found in the 
conductometric titration curves  at concentrations ratios of 0.5 and 1 which appear 
to indicate the formation of 1:2 (A to B) and 1:1 (B to C) complexes . 
 Having characterised the sites of interaction of the receptor and the composition of the 
complexes in MeCN at 298 K, we proceeded with the determination of the  thermodynamic 
parameters in this solvent using isothermal titration calorimetry (ITC).These are now reported in 
Table 2 where the stability constants (expressed as log Ks), the standard enthalpy, ΔcH° and 
entropy, ΔcS° for the interaction with aspirin, clofibric acid and diclofenac in acetonitrile at 
298.15 K are listed in this Table. The standard deviation of the data are also included. 
Table 2. Thermodynamic parameters for the complexation of 1 with pharmaceuticals in 
acetonitrile at 298.15 K 
 
Drug 
 
 
log Ks 
 
 
ΔcGo (kJ mol-1) 
 
 
ΔcHo (kJ mol-1) 
 
 
ΔSo (J mol-1 K-1) 
 
 
Clofibric acid 
 
7.30   0.05 (Eq. 4) 
6.1  0.1 (Eq. 5) 
 
-41.4  0.3 
-35.7  0.1 
 
 
 
-48.1  0.7 
14   3 
 
 
 
-23  
168 
 
Diclofenac 
 
5.8  0.7 (Eq. 4) 
5.1   0.6 (Eq.5) 
 
-33  4  
-29  3  
 
 
-34.5  0.1 
17  3. 
 
 
-4 
150 
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Aspirin 
 
3.9  0.1 (Eq. 4) 
 
-22.4  0.6 -23.0  0.3 -2 
 
 
The data for aspirin fits into a 1:1 (host: guest) complex while those for clofibric acid and 
diclofenac into 1:2 complexes. As previously stated thermodynamics does not provide 
structural information. However, it is indisputable that any model proposed must fit the 
experimental data. Therefore, the thermodynamic data are referred to the following processes, 
For 1:1 complexes of aspirin, clofibric acid and diclofenac, eq. 4 is representative of the 
process taking place in solution on the results obtained from conductance data that these 
pharmaceuticals predominantly exist as ion pairs in acetonitrile 
R COOH (MeCN) + 1 (MeCN) → RCOO- (MeCN) + H1+ (MeCN)  Eq. 4 
For 1:2 complexes of clofibric acid and diclofenac, 
RCOOH (MeCN) + H1+ (MeCN) → RCOO- (MeCN) + H212+ (MeCN)  Eq.5 
 For aspirin the process is enthalpy controlled. The same applies for the 1:1 complexes of 
clofibric acid and diclofenac. However the formation of 1:2 complexes is enthalpically 
unfavoured and entropically controlled. These results are striking and suggest that a great 
disorder in the structure of the receptor occurs to allow the entrance of the second proton. X 
ray crystallographic studies of an analogous receptor,2, with perchloric acid36 has shown the 
double protonation of the receptor as well as the loss of the solvent upon protonation while the 
hydrogen bond between the ethereal oxygen and the phenolic oxygen still remains. The 
conformational change that 1 undergoes in moving from the free to the protonated ligand as 
shown by 1H NMR studies in CD3CN indicates a flattened ‘cone’ conformation for the latter 
relative to the quasi ‘cone’ conformation of the former and as a result the hydrophobic cavity is 
able to lose the solvent. This process will lead to an increase in entropy. Given that energy 
would be required to remove the solvent from the cavity, the process would be enthalpically 
unfavoured. This interpretation is corroborated by the data reported in Table 2. Comparison of 
the protonation constants of 1 with clofibric acid and diclofenac in acetonitrile at 298.15 K 
relative to those for 2 and HClO4 in the same solvent and temperature (log Ks1=15.68, log Ks2= 
14.36) demonstrates the effect of the strength of the acid on the protonation process as well as 
the basic nature of the amine moieties in the pendant arms given that the basicity of the tertiary 
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amine in 2 is higher than that of 1 (primary amine). However the most interesting finding of this 
research is that this receptor besides having a higher capacity for clofibric acid and diclofenac 
relative to aspirin is able to recognise selectively these drug to the extent that in terms of a 1:1 
receptor: drug interaction 1 is more selective for clofibric acid relative to diclofenac and aspirin 
by factors of 32 and 2399 respectively in acetonitrile while the overall selectivity of the receptor 
for clofibric acid with respect to diclofenac is greater by a factor of 316. 
In order to get further insight regarding the different hosting capacity of 1 for aspirin relative to 
clofibric acid and diclofenac, molecular simulation calculations were carried out. The outcome 
is shown in Figure 5 where the presence of a carbonyl oxygen in the ortho position with respect 
to the carboxylic group in aspirin leads to two contact points involving the amine functionalities 
in each of the pendant arms of the receptor. Thus a proton transfer reaction occurs where one 
of the amino functionalities is protonated (as shown from conductance measurements) while 
the remaining one enters hydrogen bond formation with the carbonyl oxygen of the ester group 
of aspirin. It seems that the presence of acetonitrile in the hydrophobic cavity of the ligand pre-
organise the receptor to interact with the drug. For clofibric acid and diclofenac each amino 
group of the receptor is protonated by two units of drug. 
 
CLOFIBRIC ACID 
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DICLOFENAC 
 
 
ASPIRIN 
Figure 5. Molecular Simulation on the interaction of 1 with clofibric acid, diclofenac and aspirin 
 
Preliminary Extraction Studies of Drugs by the Calix[4]arene Receptor and Scope for the 
Design of Sensing Devices 
Given that 1 is a non-soluble receptor in water and to avoid the use of organic solvents which 
are environmentally unfriendly, preliminary batch experiments on solid-aqueous solution 
extractions using these pharmaceuticals were carried out.The results so far obtained showed 
that this receptor is able to remove 82±2 and 71±2 % of clofibric acid and diclofenac 
respectively from water (optimum pH range=7-8) while the % E was found to be very low for 
aspirin. It should be emphasised that although  it was shown that aspirin interacts with 1 in 
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acetonitrile , it is well established that the solvation properties of this solvent are very poor 
relative to water. In the latter solvent the drug is bound to be strongly hydrated and therefore a 
high competition between the solvent and the receptor for the drug occurs . As the drug is 
comfortable in water it is reluctant to interact with the receptor, reducing its capacity to remove 
the drug from water.The trend observed is  in accord  with  that observed for the stability 
constant data obtained  from thermodynamics (Table 2) and the pKa values discussed above. 
Again the capacity values obtained (mmoles of drug/ gram of material) , follows the same trend 
with values of  0.20 and 0.035 mmol/g for clofibric acid and diclofenac respectively. The 
extraction process was found to be fast (10 minutes).  No changes in the capacity of the 
receptor were found with ttemperature, this is expected given that it would depend on the 
number of sites in the material  Recycling of the material can be carried out via a pH switching 
mechanism Indeed hardly any % E is found at pH 2 due to the protonation of the receptor. 
We have recently reported52 the following correlation for a carrier mediated  mercury (II) ion 
selective electrode 
log Ks M(II) - log Ks Hg(II)= log k Hg(II), M(II)    Eq.6 
In Eq.6, Ks denotes the stability constant of the receptor and the appropriate metal cation and k 
is the selectivity coefficient of the metal cation relative to Hg(II). This correlation demonstrated 
for the first time that selectivity could be established through solution screening 
(thermodynamics) without having to construct an electrode each time. Further investigations 
will be carried out to develop a carrier mediated electrode based on 1 and to assess whether 
eq.6 is applicable to the systems reported in this paper. 
 
 Conclusions 
From the above discussion it follows that 
i) The calix[4]arene receptor is able to recognise selectively clofibric acid, diclofenac 
and aspirin and discriminates against other drugs containing calboxylic functional 
groups (cyprofloxacin, nalidixic acid and ibuprofen). The interaction is controlled by 
the dissociation constants of the acids  
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ii) The hosting ability of the receptor is greater for clofibric acid and diclofenac given 
that two protons are taken up per unit of receptor. For aspirin only one proton is 
transferred to the receptor. Molecular simulation studies suggest that for the latter 
drug , one of the amino functionalities is protonated while the remaining one enters 
hydrogen bond formation with the carbonyl oxygen of the ester group of aspirin. 
iii) Thermodynamics provides a quantitative assessment of the strength of interaction 
through the stability constant .The availability of enthalpy and entropy data allows 
to assess whether the process is enthalpy or entropically controlled. 
iv) Preliminary extraction data are encouraging as far as the use of this receptor for 
the selective removal of these drugs from water 
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